Effect of the administration of an oral hyaluronan formulation on clinical and biochemical parameters in young horses with osteochondrosis.

This study evaluated the effects of an oral hyaluronan supplement on young horses with osteochondrosis, a joint condition, and found that while the supplement was safe and well-tolerated, it did not significantly improve joint health measures compared to a placebo.

Research Objectives and Hypotheses

• The aim of the study was to investigate the impacts of oral hyaluronan supplement known as Hyal-Joint (HJ) on young horses affected by osteochondrosis (OC), a degenerative bone condition.
• This research was based around the hypotheses that the administration of HJ could help decrease symptoms of OC, like synovial effusion (swelling in the joints due to excess synovial fluid), and reduce the concentration of nitric oxide (NO) and prostaglandin E2 (PGE2), inflammatory agents in the synovial fluid.
• It was also hypothesized that HJ would increase the level of hyaluronic acid (HA) in the horse’s plasma and synovial fluid, a substance seen as beneficial to joint health.

Study Design and Methodology

• A total of 11 young horses with tarsocrural OC were enrolled in this double-blinded, placebo-controlled clinical trial, ensuring neither the subjects nor the researchers knew who received the treatment or the placebo.
• Six horses were given a daily dose of 250mg HJ for 60 days while the remaining five horses were administered a placebo.
• Parameters like synovial effusion, HA, NO, and PGE2 concentrations in plasma and synovial fluid were noted at the start of the trial, at the end of the 60-day treatment, and 30 days post-treatment.

Results of the Study

• Findings of this study revealed that there were no significant changes between the groups in terms of each parameter at the start (T0), at the end of treatment (T60), and 30 days after treatment (T90).
• However, a trend showing slightly reduced synovial effusion and increased HA, NO, and PGE2 levels in the synovial fluid was observed in horses given HJ, though these findings were statistically non-significant. This suggests the impact of the HJ treatment was not strong enough to make a significant difference.
• The dosage of 250mg/day of HJ was found safe and well-tolerated among the horses, with no adverse clinical effects reported.